APPLICATIONS PUBLISHED 13 JULY 2005

Controlled release of anti-arrhythmic agents
Genzyme 1551368*

Combination therapy for treatment of fibrotic disorders
Intermune 1551369*

Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-impermeable barriers and for the non-invasive drug application in vivo, especially through the skin
Idea AG 1551370*

Stabilised nanoparticle formulation of camtotheca derivatives
Imarx Therapeutics 1551371*

Pharmaceutical formulation comprising cyclosporin, propylene glycol ester and non-ionic surfactant
Patel, Satishchandra Punambhai 1551375*

Immunomodulatory compsns, methods of making, and methods of use thereof
Dynavax Technologies 1551376*

Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
Wyeth 1551379*

A method of treating vasomotor symptoms comprising a compound having norepinephrine reuptake inhibitor activity and 5-HT2A antagonistic activity
Wyeth 1551380*

Styrylacrylonitrile compounds for inhibition of vascular endothelial growth factor
The Hospital for Sick Children 1551381*

Prophylactic docosahexanoic acid therapy for patients with subclinical inflammation
Martek Biosciences Corp 1551382*

Methods for preventing and treating microbial infections by modulating transcription factors
Paratek Pharmaceuticals 1551383*

R-NSAID esters and their use
Encore Pharmaceuticals 1551384*

Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
Celgene Corp 1551385*

Methods and compsns for the treatment of lupis using clofarabine
Bioenvision 1551386*

PKC activation as a means for enhancing SAPPA secretion and improving cognition using bryostatin-type compounds
Blanchette Rockefeller Neurosciences Institute 1551387*

Compounds useful for the treatment of cancer, compsns thereof and methods therewith
Signal Pharmaceuticals 1551388*

Dihydroartemisinin and dihydroartemisitene dimers as anti-cancer and anti-infective agents
University of Mississippi 1551389*

Levamisole, avermectins or similar in pyrrolidone solvent
Ashmont Holdings 1551390*

Novel lapacho compounds and methods of use thereof
Arqule; Westfaelische Wilhelms-Universiaet Muenster 1551392*

Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions
Migaly, Peter 1551393*

Treatment of lower urinary tract symptoms associated with overactive bladder in men and women
Janssen Pharmaceutica 1551394*

5-HT 1B/1D receptor agonists for the treatment of headache resulting from administering an endothelin receptor antagonist
AstraZeneca 1551395*

PIN1-modulating compounds and methods of use thereof
Pintex Pharmaceuticals 1551396*

Guanidine compounds as anaesthetics and for treatment of nervous system disorders
MediQuest Therapeutics 1551397*

Pyrazolopyridines and methods of making and using the same
Biogen Idec MA 1551398*

Method for topical treatment of eye disease and compsn and device for said treatment
Babizhayev, Mark 1551399*

Preparation of triazospiro compounds
Euro-Celtique 1551400*

Mannitol formulation for integrin receptor antagonist
Merck 1551401*

Abuse-resistant pharmaceutical compsns
Verion; Elan Corp 1551402*

5-substituted 2H-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
Arena Pharmaceuticals 1551403*

Method of inhibiting angiogenesis
Abbott Laboratories 1551404*

Tiotropium salts for reducing respiratory mortality rate
Boehringer Ingelheim Pharma 1551405*

Use of indolyl derivatives for the manufacture of a medicament for the treatment of allergic rhinitis
Janssen Pharmaceutica 1551406*

Treatment of AML
Academisch Ziekenhuis Groningen 1551407*

4-(4-methylpiperazin-1-ylmethyl)-N-4-pyridin-3-yl)pyrimidin-2-ylamino)-phenyl-benzamide for treating anaplastic thyroid cancer
Novartis 1551408*

Use of the quinazoline derivative ZD6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
AstraZeneca 1551409*

Novel compounds
SmithKline Beecham Corp 1551410*

Synergistic methods and compsns for treating cancer
Bristol-Myers Squibb 1551411*

Pharmaceutical compsns for the treatment of diseases related to neurotrophines
Mimetech 1551412*

Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
Wyeth 1551413*

Crystal forms of olanzapine and processes for their preparation
Krka, DD 1551414*

Pharmaceutical application of 15- or 16-substituted testosterone analogues
Pantarhei Bioscience 1551415*

Method for treating erectile dysfunction and increasing libido in men
Unimed Pharmaceutical 1551416*

Substituted ketophosphonate compounds having bone anabolic activity
Ilex Oncology Research 1551418*

Relief of AIDS symptoms
Bio-Defense Nutritionals 1551419*

Aryl phosphate derivatives with selective activity against adenovirus and HIV
Parker Hughes Institute 1551420*

Nucleoside derivatives as inhibitors of RNA-dependant RNA viral polymerase
Merck; Isis Pharmaceuticals 1551421*

Carbohydrate based antibacterials
Alchemia 1551422*

Compsns comprising highly purified amphotericin B
University of Mississippi; University of Mississippi Medical Centre 1551423*

Treatment of neurological disorders by DSRNA administration
Novartis 1551424*

Therapeutic formulations
Kosan Biosciences 1551426*

Methods of administering FG18
ZymoGenetics 1551426*

Physiological balanced, ionised, acidic solution and methodology for use in wound healing
Novacal Pharmaceuticals 1551427*

Polymer compsns containing bioactive agents and methods for their use
Medtronic MimiMed 1551428*

Botulinum toxin dental therapies and procedures
Allergan 1551430*

Purified amylase inhibitor and novel process for obtaining the same
Pharmachem Laboratories 1551431*

Argyrolobium reseum plant extracts for treating diabetes
Council of Scientific and Industrial Research 1551432*

Compsn comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease
Pengenomics 1551433*

Identification of actinobacillus atinomycetemcomitans antigens for use in the diagnosis, treatment and monitoring of peridontal diseases
University of Florida Research Foundation 1551434*

Formulation for amylin agonist peptides
Amylin Pharmaceuticals 1551436*

Method for treatment of demyelinating central nervous system disease using GM-CSF
Hunter, Samuel F 1551444*

Compsns and methods for therapeutic treatment
Savient Pharmaceuticals 1551452*

Pharmaeutical compsn for prevention and treatment of kidney diseases
Kowa Co 1551456*

Liquid dosage compsns of stable nanoparticulate active agents
Elan Pharma International 1551457*

Clixarenes for use as excipient for an active substance
Wolf, Hans Uwe 1551458*

A method for monitoring the effectiveness of tetracycline in the treatment of asthma
Durkin, Helen; Joks, Rauno; Smith-Norowitz, Tamar; Bluth, Martin 1551460*